FDA Inspection 1202257 — LPNA Group Inc.

LPNA Group Inc. — FEI 1000120219

The FDA completed an inspection of LPNA Group Inc. on Apr 11, 2023 in Tonawanda, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 5 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Apr 11, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Tonawanda, NY (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
183321 CFR 211.84(d)(1)Identity Testing of Each Component
256721 CFR 211.198(a)Adverse Drug Experience
354721 CFR 211.46(b)Equipment for Environmental Control
440221 CFR 211.192Written record of investigation incomplete

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.